Why the same disorder looks different at every age
Note: The video and audio linked above were generated with the assistance of AI. Clinical accuracy has been reviewed, but no AI-generated content can be guaranteed to be fully error-free.
Why this spoke matters
Von Willebrand disease is often described as a lifelong bleeding disorder.
That is true.
But it can also be misleading.
The underlying abnormality may persist across decades, but the bleeding phenotype does not remain fixed. A child with recurrent epistaxis may become an adolescent with heavy menstrual bleeding. A pregnant patient may have near-normal VWF levels in the third trimester, then become vulnerable again postpartum. An older adult may have VWF levels that have risen into the normal range, while new vascular lesions, medications, or acquired von Willebrand syndrome create new bleeding risks.
The disease is not simply moving through time.
Time is modifying how the disease appears.
This is why VWD cannot be understood from a single laboratory value or a single bleeding episode. The same person may look different at different ages because VWF biology, hemostatic demand, physiologic state, and clinical interpretation all change.
By hemostatic reserve, I mean the capacity of the platelet, VWF, coagulation, vascular, and fibrinolytic systems to maintain effective hemostasis when challenged. VWD reduces that reserve, but the clinical consequences may become visible only when demand rises.
The central question is not only:
Does this patient have VWD?
It is also:
What life stage is testing the patientās hemostatic reserve now?
The same disorder, changing visibility
VWD is not equally visible at every age.
Some patients bleed early. Others appear well until menarche, dental extraction, surgery, childbirth, trauma, anticoagulation, or gastrointestinal vascular disease reveals the problem.
This does not mean the disorder appeared suddenly.
It means the hemostatic system was tested differently.
Three forces shape the life-stage phenotype:
- biologic modulation
- hemostatic challenge
- interpretive context
Biologic modulation includes age, pregnancy, inflammation, stress, exercise, hormonal state, blood group, and comorbid illness. ABO blood group is especially important for baseline VWF levels, with group O individuals generally having lower VWF levels than non-O individuals.1
Hemostatic challenge includes the events that place pressure on the system: tooth loss, nosebleeds, menstruation, surgery, childbirth, trauma, gastrointestinal vascular lesions, and medications.
Interpretive context includes what the patient, family, and clinician recognize as abnormal. A nosebleed in a child, a heavy period in an adolescent, or iron deficiency in an adult may be normalized, minimized, or misattributed.
The biology matters.
The challenge matters.
The story matters.
The life-stage framework applies across VWD subtypes, but the magnitude and direction of change vary substantially between quantitative and qualitative disorders. Pregnancy and aging may raise VWF levels in many patients with type 1 VWD or low VWF, but they do not necessarily correct qualitative dysfunction in type 2 VWD, and they do not normalize the near-absence of VWF in type 3 disease.
Childhood: pattern recognition before full testing
In childhood, VWD often presents with mucocutaneous bleeding.
Common clues include:
- recurrent epistaxis
- easy bruising
- prolonged bleeding from minor wounds
- oral mucosal bleeding
- bleeding after tooth loss
- bleeding after tonsillectomy or dental procedures
But childhood bleeding is hard to interpret.
Children bruise. Children fall. Children get nosebleeds. Many have not yet faced major hemostatic challenges. They may not have had surgery, dental extraction, trauma, menarche, or childbirth.
This means that childhood history has two limitations.
First, some bleeding symptoms are common in children without bleeding disorders.
Second, a negative history may simply reflect lack of exposure.
A child who has not bled has not necessarily passed the test. The test may not yet have occurred.
Structured bleeding assessment tools can help organize the history, but they cannot create exposure where none has happened. A low bleeding score in a young child is less reassuring than a low bleeding score in an adult who has already undergone dental extraction, surgery, or childbirth without bleeding.2
In childhood, the phenotype is often emerging, not fully declared.
Adolescence: menarche as a hemostatic stress test
For many patients, adolescence is when VWD becomes clinically visible.
Menarche may be the first repeated, physiologic, high-demand challenge to primary hemostasis. Heavy menstrual bleeding can reveal a bleeding disorder that was only faintly suggested by childhood bruising or epistaxis.
This is one reason VWD is diagnosed more often in females, despite autosomal inheritance. The genetic risk is not female-specific. The hemostatic challenge often is.3
Heavy menstrual bleeding may present as prolonged menses, flooding, clots, frequent product changes, nighttime changes, missed school, fatigue, iron deficiency, or iron deficiency anemia.4
The point is not that menarche creates VWD.
It reveals limited hemostatic reserve.
This distinction matters clinically. Heavy menstrual bleeding should not be dismissed as ānormal for her.ā Nor should it be treated only as a gynecologic symptom. In the right context, it is hematologic evidence.
Ferritin matters here. A normal hemoglobin does not exclude clinically important menstrual blood loss, particularly in patients with chronic heavy menstrual or mucosal bleeding.5
In adolescence, the life-stage question becomes:
Has menstruation become the first real test of VWF-dependent hemostasis?
Reproductive years: recurrence, normalization, and diagnostic delay
The reproductive years can amplify the VWD phenotype.
Heavy menstrual bleeding may continue for years before a diagnosis is made. Patients may adapt to symptoms they assume are normal: carrying extra pads, planning life around menses, avoiding activities, accepting fatigue, or being told that heavy bleeding is common.
But repetition does not make bleeding normal.
It makes it easier to overlook.
During these years, additional hemostatic challenges may occur: dental extraction, gynecologic procedures, miscarriage, childbirth, surgery, trauma, or anticoagulant exposure. The bleeding phenotype becomes cumulative, not because the disease necessarily worsens, but because life supplies more opportunities for bleeding to declare itself.
This is also the stage when diagnostic labels can become especially consequential. A diagnosis may affect procedure planning, pregnancy counseling, treatment access, family testing, and patient identity.
The task is to recognize clinically meaningful bleeding without overdiagnosing normal variation.
That balance requires both laboratory testing and a careful history of hemostatic challenges.
Pregnancy: physiologic rise and diagnostic ambiguity
Pregnancy is one of the clearest demonstrations that VWD is dynamic.
In many patients with type 1 VWD, VWF and factor VIII levels rise during pregnancy, often substantially. By the third trimester, levels may reach ranges that appear reassuring, especially in patients with mild quantitative deficiency.6
But pregnancy does not correct the underlying diagnosis.
It changes the laboratory environment.
This creates diagnostic ambiguity. Testing performed for the first time during pregnancy may obscure baseline VWF deficiency. A normal third-trimester value does not necessarily reflect the patientās usual hemostatic reserve.
Pregnancy produces several simultaneous shifts:
- VWF and factor VIII may rise
- bleeding risk near delivery may appear lower
- the underlying susceptibility may persist
- postpartum risk may remain important
This is why pregnancy requires anticipation rather than reassurance based on a single number.
The question is not only what the VWF level is today.
It is what the level was before pregnancy, what the bleeding history shows, and what will happen after delivery.
Postpartum: the return toward baseline
The postpartum period is a vulnerable interval in VWD.
After delivery, VWF and factor VIII levels fall back toward baseline. Bleeding may occur after the immediate delivery window, particularly as pregnancy-associated hemostatic changes recede.7
This is why postpartum bleeding can be especially instructive. It shows that bleeding risk is not determined only by genotype or by a single antepartum laboratory value.
It is shaped by timing.
VWD may present as primary postpartum hemorrhage, secondary postpartum hemorrhage, prolonged lochia, iron deficiency after delivery, need for transfusion, or need for hemostatic therapy.8
Pregnancy may temporarily improve the laboratory phenotype.
The postpartum period may reveal the baseline again.
Adulthood: the situational phenotype
Many adults with VWD do not bleed spontaneously in daily life.
Instead, bleeding becomes situational.
Dental extraction, surgery, childbirth, trauma, gynecologic procedures, gastrointestinal procedures, and anticoagulant or antiplatelet therapy may reveal hemostatic vulnerability.
This can create diagnostic confusion. A patient may say, āI do not really bleed,ā but then describe prolonged bleeding after wisdom teeth extraction, excessive postpartum bleeding, iron deficiency from heavy menses, or unexpected surgical oozing.
The adult bleeding history must therefore be read as a history of exposures.
What happened after procedures?
What happened after childbirth?
What happened after injury?
What happened when antithrombotic therapy was started?
The phenotype is not only what occurs spontaneously. It is what happens when the system is stressed.
In adulthood, VWD is often a situational bleeding disorder.
Aging: laboratory normalization and new bleeding risks
Aging complicates VWD in two directions.
First, VWF levels often rise with age. Some patients previously diagnosed with type 1 VWD or low VWF may later have VWF levels in the normal range.9
This does not necessarily mean the disease has disappeared. It may mean that the laboratory value has changed.
Whether the diagnosis should be reconsidered depends on the original diagnosis, prior bleeding phenotype, repeated historical levels, family history, and current clinical context. The 2021 diagnostic guideline emphasizes reconsidering rather than automatically removing a prior type 1 VWD diagnosis when levels normalize with age.10
Second, aging can introduce new bleeding risks.
Older adults may develop gastrointestinal angiodysplasia, cardiovascular disease, renal disease, inflammatory illness, malignancy, or exposure to antiplatelet and anticoagulant therapy. Some develop acquired von Willebrand syndrome, especially in association with severe aortic stenosis, LVAD support, myeloproliferative neoplasms, marked thrombocytosis, lymphoproliferative disease, plasma cell dyscrasia, or hypothyroidism.11
Thus aging can both attenuate and amplify bleeding risk.
VWF levels may rise.
But vascular lesions, comorbid illness, and medications may make bleeding more clinically important.
Severe VWD across life
In severe VWD, especially type 3 disease, the phenotype may be more visible from early life.
Because VWF is nearly absent, factor VIII may be markedly reduced. Patients may have mucocutaneous bleeding as well as deep tissue bleeding, muscle hematomas, hemarthroses, and procedure-related bleeding.12
For these patients, life-stage changes still matter, but the baseline vulnerability is greater.
A child with type 3 VWD may present earlier. An adolescent may face heavy menstrual bleeding. An adult may require surgical planning. An older patient may develop gastrointestinal bleeding or treatment-related complications.
Some patients with severe VWD develop recurrent bleeding patterns, including joint bleeding, severe epistaxis, heavy menstrual bleeding, or gastrointestinal bleeding, that may require long-term prophylaxis and periodic reassessment.13
Even severe VWD is not outside time.
Severity changes the baseline.
Life stage changes the expression.
What actually changes over time?
In inherited VWD, the germline VWF genotype generally does not change over time.
But phenotype does.
What changes is the relationship among biology, exposure, and interpretation.
Biologic modulation changes the measured hemostatic system:
- age
- stress
- inflammation
- pregnancy
- hormonal state
- ABO blood group
- comorbid illness
Exposure risk changes what the patient encounters:
- tooth loss
- menarche
- dental extraction
- surgery
- childbirth
- trauma
- anticoagulants
- gastrointestinal vascular lesions
Interpretive context changes how bleeding is recognized:
- what the patient considers normal
- what the family notices
- what the clinician asks
- which tests are ordered
- how borderline values are interpreted
- whether prior hemostatic challenges have occurred
The inherited defect may be constant.
The phenotype is not.
Clinical synthesis
VWD is not a fixed bleeding phenotype.
It is a dynamic hemostatic vulnerability whose clinical expression shifts with developmental stage, physiologic state, and environmental exposure.
This life-course view prevents two common errors.
The first is assuming that a mild childhood phenotype guarantees lifelong mild disease.
The second is assuming that laboratory normalization means the diagnosis has disappeared.
Neither assumption is safe.
In VWD, time is not just background.
It is a modifier of phenotype.
Evidence anchor: why VWD changes across life stages
| Evidence stream | What it shows | Why it matters | Main limitation |
|---|---|---|---|
| Pediatric presentation | Children with VWD may present with epistaxis, bruising, oral bleeding, or procedure-related bleeding, but these symptoms are also common in children without bleeding disorders.14 | Childhood bleeding histories must be interpreted against developmental exposure. | Many children have not yet experienced major hemostatic challenges. |
| Bleeding assessment tools | BATs help standardize bleeding history, but their value depends on pretest probability, age, sex, recall, and prior hemostatic challenges.15 | BATs help organize the life-stage history rather than replace clinical judgment. | Scores may underrepresent risk before meaningful challenges have occurred. |
| Adolescence and menarche | Heavy menstrual bleeding is a major manifestation of VWD and may be the first clear clinical signal in adolescents.16 | Menarche can function as a repeated physiologic test of hemostatic reserve. | Heavy menstrual bleeding is common and may have gynecologic as well as hematologic causes. |
| Pregnancy physiology | VWF and factor VIII often rise during pregnancy, especially in type 1 VWD, and may reach apparently reassuring levels near delivery.17 | Pregnancy can temporarily improve laboratory reserve and complicate diagnosis. | Pregnancy values may obscure the patientās baseline phenotype. |
| Postpartum bleeding | VWF and factor VIII fall after delivery, and postpartum bleeding remains an important risk in VWD.18 | The postpartum period shows how timing can change bleeding risk even when pregnancy levels were reassuring. | Risk varies by subtype, baseline levels, delivery course, treatment, and obstetric factors. |
| Aging and VWF levels | VWF levels often rise with age, and some patients with prior type 1 VWD or low VWF may later have levels in the normal range.19 | Laboratory normalization should prompt reconsideration, not automatic erasure, of the diagnosis. | The relationship between rising VWF levels and bleeding improvement remains uncertain. |
| Acquired VWS and late-life bleeding | Older adults may develop acquired VWF defects from high-shear cardiovascular lesions, LVAD support, myeloproliferative disease, plasma cell or lymphoproliferative disorders, hypothyroidism, or other conditions.20 | New bleeding in later life should not automatically be attributed to inherited VWD or aging alone. | High-shear forms of acquired VWS can mimic inherited type 2A-like patterns and require context-specific evaluation. |
| Severe VWD | Type 3 VWD and severe VWD can present early and may include mucosal bleeding, procedure-related bleeding, muscle bleeding, and hemarthroses because FVIII may be markedly reduced.21 | Severe VWD has a broader bleeding vocabulary than mild mucocutaneous disease. | Referral cohorts may overrepresent severe phenotypes. |
Interpretive note: Life-stage changes do not mean the diagnosis is repeatedly changing. They mean the same hemostatic vulnerability is being modified by biology, exposure, and time.
Clinical guidance: using life stage to interpret VWD
In children, ask what has not happened yet
A child without surgical bleeding may simply never have had surgery. Absence of bleeding is most informative when meaningful hemostatic challenges have occurred.
At menarche, treat heavy menstrual bleeding as a diagnostic event
Heavy menstrual bleeding may be the first major physiologic test of VWF-dependent hemostasis. Ask about flooding, clots, hourly product changes, nighttime changes, school absence, anemia, and ferritin.
During pregnancy, do not confuse physiologic rise with cure
VWF and factor VIII may rise during pregnancy, especially in type 1 VWD. A reassuring third-trimester value does not necessarily represent baseline.
Postpartum, anticipate the fall
Postpartum bleeding risk reflects the return toward baseline after delivery. Secondary postpartum hemorrhage should be part of anticipatory counseling and management planning.
In adults, read the history as exposure history
Ask about dental extraction, surgery, childbirth, trauma, anticoagulants, antiplatelet therapy, and mucosal procedures. Daily life may not be the strongest test of VWF-dependent hemostasis.
In older adults, reconsider both directions
Rising VWF levels may make prior laboratory abnormalities less apparent, but age-related vascular disease, medications, comorbidities, and acquired VWS may create new bleeding risk.
In severe VWD, expect early visibility but still ask about context
Type 3 and severe VWD often declare themselves early, but bleeding burden still depends on activity, access to care, procedures, trauma, menses, pregnancy, and comorbid illness.Guideline perspective: managing absence rather than deficiency
Reflect & Apply Case
A 12-year-old girl is evaluated for recurrent epistaxis and easy bruising.
Her testing shows:
- VWF antigen 42 IU/dL
- platelet-dependent VWF activity 39 IU/dL
- mildly reduced factor VIII activity
- preserved activity-to-antigen ratio
She is labeled as having type 1 VWD.
At 17, she develops heavy menstrual bleeding and iron deficiency.
At 28, during pregnancy, her VWF level rises to 95 IU/dL.
At 34, she has delayed postpartum bleeding after her second delivery.
At 55, her VWF level is 78 IU/dL and she reports little spontaneous bleeding.
Questions for reflection:
Did her disease change at each life stage?
Which parts of the story reflect VWF biology?
Which parts reflect hemostatic challenge?
Which parts reflect physiologic modulation?
How would you explain the normal pregnancy or later-life VWF levels to her?
Would you remove the diagnosis at age 55?
What would you want to know before surgery?
The point is not that she has four different diseases.
The point is that the same hemostatic vulnerability can become visible, hidden, amplified, or reinterpreted as life changes.
In VWD, time is part of the phenotype.
Test your thinking
An interactive quiz for this topic is being developed and will be added soon.